Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Biocompatible intermittent hemodialysis

S Lang1, C Küchle, H Fricke

  • 1Medizinische Klinik, Klinikum Innenstadt, Universität München, Germany.

New Horizons (Baltimore, Md.)
|November 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term renal consequences of COVID-19. Emerging evidence and unanswered questions.

International urology and nephrology·2025
Same author

Intensive care unit continuous kidney replacement therapy: time to change dosage recommendations?

International urology and nephrology·2024
Same author

Adult macrophage activation syndrome-haemophagocytic lymphohistiocytosis: 'of plasma exchange and immunosuppressive escalation strategies' - a single centre reflection.

Lupus·2020
Same author

[Exercise training in the therapy of heart diseases: Current evidence and future options].

Herz·2016
Same author

Multifocal primary amyloidosis of the airways: Case report and review of the literature.

Respiratory medicine case reports·2015
Same author

Sentinel Lymph Node Biopsy in Patients with Breast Cancer: Comparison of Peritumoral and Periareolar Injection.

Geburtshilfe und Frauenheilkunde·2014
Same journal

Palliative care in the intensive care unit.

New horizons (Baltimore, Md.)·2001
Same journal

An international perspective on the treatment of pediatric shock: the Brazilian experience.

New horizons (Baltimore, Md.)·1998
Same journal

Nutrition and shock in pediatric patients.

New horizons (Baltimore, Md.)·1998
Same journal

Recent advances in pediatric cardiopulmonary resuscitation and advanced life support.

New horizons (Baltimore, Md.)·1998
Same journal

Potential protective role of the heat shock response in sepsis.

New horizons (Baltimore, Md.)·1998
Same journal

Molecular biology of septic shock.

New horizons (Baltimore, Md.)·1998
See all related articles

Using biocompatible dialysis membranes in critically ill patients with acute renal failure (ARF) significantly reduces mortality. These membranes mitigate adverse bioincompatibility reactions, improving patient outcomes and renal function recovery.

Area of Science:

  • Nephrology
  • Critical Care Medicine
  • Biomaterials Science

Background:

  • Acute renal failure (ARF) in critically ill patients has a high mortality rate, potentially linked to dialysis membrane bioincompatibility.
  • Improved resuscitation and intensive care allow sicker patients to develop ARF, challenging previous survival assumptions.

Purpose of the Study:

  • To investigate the impact of dialysis membrane biocompatibility on ARF patient outcomes.
  • To test the hypothesis that bioincompatibility reactions (complement and neutrophil activation) adversely affect ARF course and survival.

Main Methods:

  • Prospective randomized trials comparing bioincompatible cuprophane (CUP) with biocompatible acrylonitrile AN 69 membranes in ARF patients post-cardiovascular surgery.
  • A similar trial comparing CUP with biocompatible polymethyl-methacrylate (PMMA) in medical ARF patients.

Related Experiment Videos

  • Analysis of preliminary results from a multicenter study involving various membrane types.

    • Main Results:

    • Biocompatible AN 69 membranes showed a lower death rate (38% vs. 65%) and reduced Gram-negative sepsis mortality (40% vs. 71%) compared to CUP.
    • Biocompatible PMMA membranes improved survival rates (57% vs. 37%) and renal function recovery (62% vs. 37%) in medical ARF patients.
    • Higher survival rates were observed with PMMA (80%) versus CUP (40%) in nonoliguric ARF patients.

    Conclusions:

    • Biocompatible dialysis membranes appear to improve survival and renal function recovery in critically ill ARF patients.
    • The use of biocompatible membranes is justified, adding minimal cost to overall patient management.
    • Findings suggest bioincompatibility reactions play a significant role in ARF patient outcomes.